Growth Metrics

Bioventus (BVS) Divestments (2022 - 2023)

Bioventus posted quarterly Divestments of -$46.4 million for Q4 2023, down 200.0% on a QoQ basis from $46.4 million in Q3 2023.

Bioventus (BVS) has 2 years of Divestments data on file, last reported at -$46.4 million in Q4 2023.

  • For the quarter ending Q4 2023, Divestments changed N/A year-over-year to -$46.4 million; the trailing twelve-month figure through Sep 2024 stood at -$46.4 million (down 232.97% YoY), and the FY2023 full-year result was -$11.5 million, up 89.03% from the prior year.
  • Divestments for Q4 2023 stood at -$46.4 million, down from $46.4 million in the prior quarter.
  • Across five years, Divestments topped out at $46.4 million in Q3 2023 and bottomed at -$104.8 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Divestments (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Bioventus 535.01 Mn 544.52 Mn 90.77 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 -46.40 Mn
Sep 30, 2023 46.40 Mn
Apr 1, 2023 -11.51 Mn
Oct 1, 2022 -104.84 Mn